RNA MARKERS OF ANTIBIOTIC-RESISTANT M TUBERCULOSIS

Information

  • Research Project
  • 2070848
  • ApplicationId
    2070848
  • Core Project Number
    R01AI035280
  • Full Project Number
    5R01AI035280-02
  • Serial Number
    35280
  • FOA Number
    RFA-AI-93-303
  • Sub Project Id
  • Project Start Date
    9/30/1993 - 31 years ago
  • Project End Date
    2/28/1995 - 29 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/1994 - 30 years ago
  • Budget End Date
    2/28/1995 - 29 years ago
  • Fiscal Year
    1994
  • Support Year
    2
  • Suffix
  • Award Notice Date
    8/11/1994 - 30 years ago
Organizations

RNA MARKERS OF ANTIBIOTIC-RESISTANT M TUBERCULOSIS

The goal is to evaluate the use of DNA probes for transient RNA molecules in testing the susceptibility of Mycobacterium tuberculosis to antibiotics. We will evaluate two types of transient RNA as indicators of antibiotic-resistant metabolic activity in cultures or clinical samples challenged briefly with antibiotics. First, we will clone, sequence, and develop DNA probes for M. tuberculosis ribosomal RNA (rRNA) precursor sequences. Second, we will use differential or subtractive screening techniques to identify specific messenger RNA (mRNA) sequences which, due to regulatory response to antibiotic challenge and mRNA turnover, are depleted in susceptible cells exposed to isoniazid, ethambutol, or streptomycin. DNA probes for these mRNAs will be developed and tested. Probes for both types of transient RNA will be combined with probes for species-specific nucleic acid sequences to result in assays that can rapidly and simultaneously detect M. tuberculosis and test its susceptibility to antibiotics. As a functional assay for antibiotic effectiveness, this general approach will be able to detect antibiotic resistance rapidly and specifically, regardless of the genetic basis for resistance. This work will also provide us with useful data on the biology of growth and ribosome assembly in M. tuberculosis, and may add to our understanding of the modes of action of important antituberculosis drugs.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SRC
  • Study Section Name
  • Organization Name
    EPOCH BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BOTHELL
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    980213906
  • Organization District
    UNITED STATES